Oct 2026· Journal of Drug Delivery and Therapeutics· Vol 16, pp. 165-178· 0 citations· 77 references
TL;DR
A well-designed etodolac floating in-situ gel may provide prolonged gastric residence and controlled drug delivery, although in-vivo gastric-retention and pharmacokinetic studies are required to establish its clinical advantage.
Abstract
Etodolac is a non-steroidal anti-inflammatory drug (NSAID) used for the management of pain and inflammatory disorders. Although conventional oral administration provides effective systemic exposure, the relatively short terminal half-life and rapid gastrointestinal transit may necessitate repeated administration and may produce fluctuating drug concentrations. Gastroretective drug delivery systems (GRDDS), particularly floating oral in-situ gels, provide an attractive approach for prolonging gastric residence and regulating drug release. This review and experimental framework focus on the development of a floating oral in-situ gel of etodolac using suitable hydrophilic and ion-responsive polymers. The formulation is designed to remain in the stomach by generating a low-density, gelled structure following contact with gastric fluid. Sodium alginate, gellan gum, hydroxypropyl methylcellulose (HPMC) and suitable gas-generating agents can be investigated to achieve rapid gelation, adequate floating ability, appropriate viscosity and sustained drug release. Important formulation and evaluation parameters include appearance, pH, viscosity, gelation characteristics, floating lag time, total floating duration, drug content, swelling, in-vitro dissolution, release kinetics and stability. Optimization of polymer concentration and polymer combinations is essential because viscosity, gel strength, buoyancy and drug diffusion are interdependent. A well-designed etodolac floating in-situ gel may provide prolonged gastric residence and controlled drug delivery, although in-vivo gastric-retention and pharmacokinetic studies are required to establish its clinical advantage.
Keywords: Etodolac; Floating in-situ gel; Gastroretective drug delivery; Sodium alginate; Sustained release
: Gastric ulcer is a common gastrointestinal disorder resulting from an imbalance between aggressive factors such as gastric acid, pepsin, oxidative stress, and inflammatory mediators and the protective mechanisms of the gastric mucosa. Coixol, a bioactive constituent isolated from Coix lachryma-jobi L., possesses sign...
Rutika Chandgude, Utkarsha Lasure· International Journal of Dru...· 0 citations
Background: Gastroretentive floating drug delivery systems can prolong gastric residence and provide sustained drug release. Natural polymers such as Tara gum offer useful swelling and hydration properties for developing controlled-release matrix tablets.
Objective: This study aimed to develop and evaluate clindamycin...
Sourav Patidar, Arpit Gawshinde, U. Atneriya et al.· International journal of res...· 0 citations
Background
Gastroretentive dosage forms are designed to remain in the stomach for an extended period and may improve drug delivery when absorption is favored in the upper gastrointestinal tract or is influenced by gastrointestinal pH. Domperidone maleate and famotidine are used in the management of upper gastrointesti...
Jakir Husain· International Journal of Pha...· 0 citations
It is suggested that the formulated liposome-based transdermal colchicine formulation has potential as a topical delivery system for gout management and warrants further preclinical and clinical evaluation.
Sushmita Yelwe, G. Bhagwat, Vijay N. Gokarn et al.· International Journal of Dru...· 0 citations
This study aimed to develop and evaluate a floating oral in situ gel with leflunomide (LEF) as a liquid gastro-retentive drug delivery system to increase the residence time of the drug in the stomach and sustain drug delivery. Floating in situ gel system of leflunomide was prepared using sodium alginate as a gelling po...
A. Ramadan, A. Elbakry, Asmaa H. Esmaeil· Brazilian Journal of Pharmac...· 0 citations
Tolfenamic acid (TFA), a Biopharmaceutics Classification System (BCS) class II drug, exhibits dissolution-limited absorption and significant gastric irritation when administered as conventional immediate-release formulations, limiting its potential for high-dose and long-term applications, including emerging anticancer...
B. P. Dongala, M. Nutan, M. Abdelrahim et al.· International journal of pha...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.